{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:51:38Z","timestamp":1793105498975,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.wneu.2024.07.175","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:36:12Z","timestamp":1722584172000},"page":"291-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2\u03b1 in Hemangioblastomas with Belzutifan"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7413-9708","authenticated-orcid":false,"given":"Andrew D.","family":"Pumford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-6617","authenticated-orcid":false,"given":"Megan","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8577-1677","authenticated-orcid":false,"given":"Samantha","family":"Bouchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-4345","authenticated-orcid":false,"given":"Cecile","family":"Riviere-Cazaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-1912","authenticated-orcid":false,"given":"Ignacio","family":"Jusue-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukwoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-0000","authenticated-orcid":false,"given":"Bryan J.","family":"Neth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3919-7408","authenticated-orcid":false,"given":"Ugur","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8047","authenticated-orcid":false,"given":"Ian F.","family":"Parney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2024.07.175_bib1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"Von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2024.07.175_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/neuonc\/noac234","article-title":"Neurological applications of belzutifan in von Hippel-Lindau disease","volume":"25","author":"Zhang","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib3","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000002555","article-title":"VON HIPPEL-LINDAU DISEASE: update on pathogenesis and systemic aspects","volume":"39","author":"Aronow","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.wneu.2024.07.175_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ICB.0000000000001376","article-title":"Two cases of von Hippel-Lindau syndrome-associated retinal hemangioblastoma treated with Belzutifan","volume":"18","author":"Grimes","year":"2022","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.wneu.2024.07.175_bib5","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2022-0008","article-title":"First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma","volume":"11","author":"Dhawan","year":"2022","journal-title":"CNS Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2024.07.175_bib7","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.wneu.2024.07.175_bib8","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2024.07.175_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2024.07.175_bib10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2024.07.175_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1541-7786.MCR-11-0053","article-title":"Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha","volume":"9","author":"Lin","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.wneu.2024.07.175_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2021.1925248","article-title":"MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma","volume":"30","author":"Hasanov","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.wneu.2024.07.175_bib13","first-page":"24","article-title":"Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome","volume":"70","author":"Neumann","year":"1989","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2024.07.175_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-022-04021-8","article-title":"Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas","volume":"159","author":"Takami","year":"2022","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib15","first-page":"971","article-title":"Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease","volume":"124","author":"Huntoon","year":"2016","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2024.07.175_bib16","first-page":"1055","article-title":"Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease","volume":"120","author":"Lonser","year":"2014","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2024.07.175_bib17","first-page":"210","article-title":"Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease","volume":"108","author":"Jagannathan","year":"2008","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2024.07.175_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10143-020-01305-3","article-title":"Safety and efficacy of surgical treatment for brainstem hemangioblastoma: a meta-analysis","volume":"44","author":"Yin","year":"2021","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.wneu.2024.07.175_bib19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib20","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1752-1947-6-238","article-title":"Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report","volume":"6","author":"Omar","year":"2012","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.wneu.2024.07.175_bib22","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.drudis.2019.09.008","article-title":"Allosteric inhibition of HIF-2alpha as a novel therapy for clear cell renal cell carcinoma","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.wneu.2024.07.175_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-023-04395-3","article-title":"Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience","volume":"164","author":"Neth","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-023-04496-z","article-title":"The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience","volume":"165","author":"Zamarud","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib25","article-title":"Fatal intracranial hemorrhage with Belzutifan in von Hippel-Lindau disease-associated hemangioblastoma: a case report","volume":"7","author":"Saeed","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.wneu.2024.07.175_bib27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1055\/a-1946-4604","article-title":"Embolization of large and giant posterior fossa hemangioblastomas: the experience of a single tertiary care center","volume":"84","author":"Bauman","year":"2023","journal-title":"J\u00a0Neurol Surg B Skull Base"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024013159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024013159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T01:28:47Z","timestamp":1749691727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875024013159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"alternative-id":["S1878875024013159"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2024.07.175","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2\u03b1 in Hemangioblastomas with Belzutifan","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2024.07.175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}